TYPHIM Vi Rx
Generic Name and Formulations:
Typhoid vaccine cell; surface purified Vi polysaccharide 25micrograms per 0.5mL; soln; for IM inj; contains phenol.
Sanofi Pasteur, Inc.
Indications for TYPHIM Vi:
Immunization against typhoid fever.
Give at least 2 weeks before expected exposure; may repeat every 2 years. Adults: 0.5mL IM once in deltoid.
≥2yrs: 0.5mL in deltoid or vastus lateralis.
Not for use in chronic carriers or patients with active infection.
Have epinephrine (1:1000) inj available. Immunocompromised states. Previous typhoid vaccination. Thrombocytopenia. Coagulopathies. Acute infection. Active febrile illness. Exposure to contaminated food and water should be avoided. Pregnancy (Cat.C). Nursing mothers.
Local reactions, malaise, headache, GI upset, myalgia, fever.
Multidose vials—contact manufacturer
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics